Gastroenterology

Gastroenterology

Volume 159, Issue 1, July 2020, Pages 350-357
Gastroenterology

Clinical Practice Updates
AGA Clinical Practice Update on Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: Expert Commentary

https://doi.org/10.1053/j.gastro.2020.04.012Get rights and content

The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update was to rapidly review the emerging evidence and provide timely expert recommendations regarding the management of patients with inflammatory bowel disease during the coronavirus disease 2019 pandemic. This expert commentary was commissioned and approved by the AGA Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely perspective on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Gastroenterology.

Keywords

IBD
Crohn’s Disease
Ulcerative Colitis
Coronavirus
SARS-CoV-2
Immunosuppression

Abbreviations used in this paper

ACE2
angiotensin-converting enzyme 2
AGA
American Gastroenterological Association
COVID-19
coronavirus disease 2019
GI
gastrointestinal
IBD
inflammatory bowel disease
IOIBD
International Organization for the Study of Inflammatory Bowel Disease
SARS-CoV
severe acute respiratory syndrome coronavirus

Cited by (0)

Conflicts of interest These authors disclose the following: David T. Rubin has received grant support from Takeda; has served as a consultant for Abbvie, Abgenomics, Allergan Inc, Boehringer Ingelheim Ltd, Bristol-Myers Squibb, Celgene Corp/Syneos, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GlaxoSmithKline Services, Janssen Pharmaceuticals, Eli Lilly, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda, and Techlab Inc. Russell D. Cohen serves on the speakers' bureau for Abbvie and Takeda. He is a consultant for Abbvie, BMS/Celgene, Eli Lilly, Gilead Sciences, Janssen, Pfizer, Takeda, and UCB Pharma. He is principal investigator or has received grants from Abbvie, BMS/Celgene, Boehringer Ingelheim, Crohn’s & Colitis Foundation, Genentech, Gilead Sciences, Hollister, Medimmune, Mesoblast Ltd, Osiris Therapeutics, Pfizer, Receptos, RedHill Biopharma, Sanofi-Aventis, Schwarz Pharma, Seres Therapeutics, Takeda Pharma, and UCB Pharma. His spouse is on the Board of Directors at Aerpio Therapeutics, Novus Therapeutics (Board of Directors), and NantKwest. The remaining authors disclose no conflicts.

View Abstract